Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease.
Identifieur interne : 000878 ( PubMed/Curation ); précédent : 000877; suivant : 000879Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease.
Auteurs : Véronique Sgambato-Faure [France] ; Maria Angela CenciSource :
- Progress in neurobiology [ 1873-5118 ] ; 2012.
English descriptors
- KwdEn :
- Animals, Basal Ganglia (metabolism), Basal Ganglia (physiopathology), Deep Brain Stimulation (adverse effects), Dopamine (adverse effects), Dopamine (therapeutic use), Dyskinesia, Drug-Induced (physiopathology), Glutamic Acid (metabolism), Humans, Parkinson Disease (physiopathology), Parkinson Disease (therapy), Receptors, AMPA (metabolism), Receptors, Metabotropic Glutamate (metabolism), Receptors, N-Methyl-D-Aspartate (metabolism).
- MESH :
- chemical , adverse effects : Dopamine.
- adverse effects : Deep Brain Stimulation.
- metabolism : Basal Ganglia, Glutamic Acid, Receptors, AMPA, Receptors, Metabotropic Glutamate, Receptors, N-Methyl-D-Aspartate.
- physiopathology : Basal Ganglia, Dyskinesia, Drug-Induced, Parkinson Disease.
- chemical , therapeutic use : Dopamine.
- therapy : Parkinson Disease.
- Animals, Humans.
Abstract
Dyskinesias represent a major complication of dopamine replacement therapy in Parkinson's disease (PD) and have prompted a search for alternative treatments. The most radical advances in this field have been provided by surgical manipulations of the deep basal ganglia nuclei, and particularly by deep brain stimulation (DBS) of the subthalamic nucleus (STN). Although being very effective, high-frequency stimulation (HFS) of the STN is a poorly understood treatment. Besides its anti-akinetic activity, it can be pro-dyskinetic above a certain stimulation intensity. Accumulating evidence indicates that dyskinesias induced by STN-HFS and dopamine replacement therapy are linked to dysregulation of glutamate transmission in the basal ganglia. In rat models of PD, both types of dyskinesia are associated with increased concentrations of extracellular glutamate and altered expression of glutamate transporters in the substantia nigra pars reticulata and the striatum. Furthermore, a vast and ever growing literature has revealed changes in the expression, phosphorylation state, and/or subcellular distribution of specific subtypes of glutamate receptors in these dyskinetic conditions. Both types of dyskinesias are linked to an increased phosphorylation of NR2B-containing NMDA receptors in critical basal ganglia circuits. We conclude that disruption of glutamate homeostasis and activation of perisynaptic and extra-synaptic glutamate receptors are an important pathophysiological component of these treatment-induced dyskinesias in PD. These findings lay the ground for therapeutic development initiatives targeting dysfunctional components of glutamate transmission in the basal ganglia.
DOI: 10.1016/j.pneurobio.2011.10.005
PubMed: 22075179
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000918
Links to Exploration step
pubmed:22075179Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease.</title><author><name sortKey="Sgambato Faure, Veronique" sort="Sgambato Faure, Veronique" uniqKey="Sgambato Faure V" first="Véronique" last="Sgambato-Faure">Véronique Sgambato-Faure</name><affiliation wicri:level="1"><nlm:affiliation>Physiopathology of basal ganglia team, Centre de Neuroscience Cognitive, Centre National de la Recherche Scientifique UMR 5229-Université de Lyon I, Bron F-69675 cedex, France. veronique.sgambato-faure@isc.cnrs.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Physiopathology of basal ganglia team, Centre de Neuroscience Cognitive, Centre National de la Recherche Scientifique UMR 5229-Université de Lyon I, Bron F-69675 cedex</wicri:regionArea></affiliation></author><author><name sortKey="Cenci, Maria Angela" sort="Cenci, Maria Angela" uniqKey="Cenci M" first="Maria Angela" last="Cenci">Maria Angela Cenci</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:22075179</idno><idno type="pmid">22075179</idno><idno type="doi">10.1016/j.pneurobio.2011.10.005</idno><idno type="wicri:Area/PubMed/Corpus">000918</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000918</idno><idno type="wicri:Area/PubMed/Curation">000878</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000878</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease.</title><author><name sortKey="Sgambato Faure, Veronique" sort="Sgambato Faure, Veronique" uniqKey="Sgambato Faure V" first="Véronique" last="Sgambato-Faure">Véronique Sgambato-Faure</name><affiliation wicri:level="1"><nlm:affiliation>Physiopathology of basal ganglia team, Centre de Neuroscience Cognitive, Centre National de la Recherche Scientifique UMR 5229-Université de Lyon I, Bron F-69675 cedex, France. veronique.sgambato-faure@isc.cnrs.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Physiopathology of basal ganglia team, Centre de Neuroscience Cognitive, Centre National de la Recherche Scientifique UMR 5229-Université de Lyon I, Bron F-69675 cedex</wicri:regionArea></affiliation></author><author><name sortKey="Cenci, Maria Angela" sort="Cenci, Maria Angela" uniqKey="Cenci M" first="Maria Angela" last="Cenci">Maria Angela Cenci</name></author></analytic><series><title level="j">Progress in neurobiology</title><idno type="eISSN">1873-5118</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Basal Ganglia (metabolism)</term><term>Basal Ganglia (physiopathology)</term><term>Deep Brain Stimulation (adverse effects)</term><term>Dopamine (adverse effects)</term><term>Dopamine (therapeutic use)</term><term>Dyskinesia, Drug-Induced (physiopathology)</term><term>Glutamic Acid (metabolism)</term><term>Humans</term><term>Parkinson Disease (physiopathology)</term><term>Parkinson Disease (therapy)</term><term>Receptors, AMPA (metabolism)</term><term>Receptors, Metabotropic Glutamate (metabolism)</term><term>Receptors, N-Methyl-D-Aspartate (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Dopamine</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Deep Brain Stimulation</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Basal Ganglia</term><term>Glutamic Acid</term><term>Receptors, AMPA</term><term>Receptors, Metabotropic Glutamate</term><term>Receptors, N-Methyl-D-Aspartate</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Basal Ganglia</term><term>Dyskinesia, Drug-Induced</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dopamine</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Dyskinesias represent a major complication of dopamine replacement therapy in Parkinson's disease (PD) and have prompted a search for alternative treatments. The most radical advances in this field have been provided by surgical manipulations of the deep basal ganglia nuclei, and particularly by deep brain stimulation (DBS) of the subthalamic nucleus (STN). Although being very effective, high-frequency stimulation (HFS) of the STN is a poorly understood treatment. Besides its anti-akinetic activity, it can be pro-dyskinetic above a certain stimulation intensity. Accumulating evidence indicates that dyskinesias induced by STN-HFS and dopamine replacement therapy are linked to dysregulation of glutamate transmission in the basal ganglia. In rat models of PD, both types of dyskinesia are associated with increased concentrations of extracellular glutamate and altered expression of glutamate transporters in the substantia nigra pars reticulata and the striatum. Furthermore, a vast and ever growing literature has revealed changes in the expression, phosphorylation state, and/or subcellular distribution of specific subtypes of glutamate receptors in these dyskinetic conditions. Both types of dyskinesias are linked to an increased phosphorylation of NR2B-containing NMDA receptors in critical basal ganglia circuits. We conclude that disruption of glutamate homeostasis and activation of perisynaptic and extra-synaptic glutamate receptors are an important pathophysiological component of these treatment-induced dyskinesias in PD. These findings lay the ground for therapeutic development initiatives targeting dysfunctional components of glutamate transmission in the basal ganglia.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22075179</PMID><DateCreated><Year>2012</Year><Month>01</Month><Day>24</Day></DateCreated><DateCompleted><Year>2012</Year><Month>05</Month><Day>07</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-5118</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Progress in neurobiology</Title><ISOAbbreviation>Prog. Neurobiol.</ISOAbbreviation></Journal><ArticleTitle>Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>69-86</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pneurobio.2011.10.005</ELocationID><Abstract><AbstractText>Dyskinesias represent a major complication of dopamine replacement therapy in Parkinson's disease (PD) and have prompted a search for alternative treatments. The most radical advances in this field have been provided by surgical manipulations of the deep basal ganglia nuclei, and particularly by deep brain stimulation (DBS) of the subthalamic nucleus (STN). Although being very effective, high-frequency stimulation (HFS) of the STN is a poorly understood treatment. Besides its anti-akinetic activity, it can be pro-dyskinetic above a certain stimulation intensity. Accumulating evidence indicates that dyskinesias induced by STN-HFS and dopamine replacement therapy are linked to dysregulation of glutamate transmission in the basal ganglia. In rat models of PD, both types of dyskinesia are associated with increased concentrations of extracellular glutamate and altered expression of glutamate transporters in the substantia nigra pars reticulata and the striatum. Furthermore, a vast and ever growing literature has revealed changes in the expression, phosphorylation state, and/or subcellular distribution of specific subtypes of glutamate receptors in these dyskinetic conditions. Both types of dyskinesias are linked to an increased phosphorylation of NR2B-containing NMDA receptors in critical basal ganglia circuits. We conclude that disruption of glutamate homeostasis and activation of perisynaptic and extra-synaptic glutamate receptors are an important pathophysiological component of these treatment-induced dyskinesias in PD. These findings lay the ground for therapeutic development initiatives targeting dysfunctional components of glutamate transmission in the basal ganglia.</AbstractText><CopyrightInformation>Copyright © 2011 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sgambato-Faure</LastName><ForeName>Véronique</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Physiopathology of basal ganglia team, Centre de Neuroscience Cognitive, Centre National de la Recherche Scientifique UMR 5229-Université de Lyon I, Bron F-69675 cedex, France. veronique.sgambato-faure@isc.cnrs.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cenci</LastName><ForeName>Maria Angela</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>11</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Prog Neurobiol</MedlineTA><NlmUniqueID>0370121</NlmUniqueID><ISSNLinking>0301-0082</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C121001">NR2B NMDA receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018091">Receptors, AMPA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018094">Receptors, Metabotropic Glutamate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>3KX376GY7L</RegistryNumber><NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001479" MajorTopicYN="N">Basal Ganglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046690" MajorTopicYN="N">Deep Brain Stimulation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004409" MajorTopicYN="N">Dyskinesia, Drug-Induced</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018698" MajorTopicYN="N">Glutamic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018091" MajorTopicYN="N">Receptors, AMPA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018094" MajorTopicYN="N">Receptors, Metabotropic Glutamate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>06</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>5</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22075179</ArticleId><ArticleId IdType="pii">S0301-0082(11)00192-4</ArticleId><ArticleId IdType="doi">10.1016/j.pneurobio.2011.10.005</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000878 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000878 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:22075179
|texte= Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:22075179" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |